Avid Bioservices Inkomsten in het verleden

Verleden criteriumcontroles 0/6

De winst van Avid Bioservices is gedaald met een gemiddeld jaarlijks percentage van -16.5%, terwijl de winst van de Biotechs -industrie jaarlijks groeide met 19.1%. De inkomsten zijn groeide met een gemiddeld percentage van 19.1% per jaar.

Belangrijke informatie

-16.5%

Groei van de winst

-15.1%

Groei van de winst per aandeel

Biotechs Groei van de industrie	17.0%
Inkomstengroei	19.1%
Rendement op eigen vermogen	-245.9%
Nettomarge	-101.3%
Laatste winstupdate	31 Jul 2024

Recente prestatie-updates uit het verleden

Recent updates

Is Avid Bioservices (NASDAQ:CDMO) Using Too Much Debt?

Aug 26

Avid Bioservices, Inc. (NASDAQ:CDMO) Surges 43% Yet Its Low P/S Is No Reason For Excitement

Jul 29

There's No Escaping Avid Bioservices, Inc.'s (NASDAQ:CDMO) Muted Revenues Despite A 40% Share Price Rise

Mar 07

We Think Avid Bioservices (NASDAQ:CDMO) Has A Fair Chunk Of Debt

Feb 28

There's No Escaping Avid Bioservices, Inc.'s (NASDAQ:CDMO) Muted Revenues Despite A 39% Share Price Rise

Dec 28

Does Avid Bioservices (NASDAQ:CDMO) Have A Healthy Balance Sheet?

Nov 10

Calculating The Intrinsic Value Of Avid Bioservices, Inc. (NASDAQ:CDMO)

Oct 15

Time To Worry? Analysts Are Downgrading Their Avid Bioservices, Inc. (NASDAQ:CDMO) Outlook

Jun 23

Is Avid Bioservices (NASDAQ:CDMO) Using Too Much Debt?

Jun 12

Little Excitement Around Avid Bioservices, Inc.'s (NASDAQ:CDMO) Earnings As Shares Take 26% Pounding

May 21

Avid Bioservices GAAP EPS of $0.02 beats by $0.01, revenue of $36.7M beats by $3.26M

Sep 06

Laughing Water Capital - Avid Bioservices: Not A Binary Bet But A Real Business

Jul 27

Opbrengsten en kosten

Hoe Avid Bioservices geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

NasdaqCM:CDMO Opbrengsten, kosten en inkomsten (USD Millions )
Datum	Inkomsten	Inkomsten	G+A Uitgaven	R&D-uitgaven
31 Jul 24	142	-144	28	0
30 Apr 24	140	-141	26	0
31 Jan 24	137	-18	27	0
31 Oct 23	141	-12	27	0
31 Jul 23	150	-3	28	0
30 Apr 23	149	0	28	0
31 Jan 23	141	116	26	0
31 Oct 22	134	119	25	0
31 Jul 22	126	123	23	0
30 Apr 22	120	128	21	0
31 Jan 22	116	10	20	0
31 Oct 21	106	9	19	0
31 Jul 21	101	6	18	0
30 Apr 21	96	3	17	0
31 Jan 21	81	0	16	0
31 Oct 20	73	-5	15	0
31 Jul 20	70	-7	14	0
30 Apr 20	60	-15	15	0
31 Jan 20	64	-10	15	0
31 Oct 19	64	-9	15	0
31 Jul 19	56	-11	14	0
30 Apr 19	54	-10	13	0
31 Jan 19	43	-16	13	0
31 Oct 18	37	-24	15	0
31 Jul 18	39	-30	16	0
30 Apr 18	54	-25	16	0
31 Jan 18	65	-17	18	0
31 Oct 17	69	6	17	-16
31 Jul 17	79	11	18	-9
30 Apr 17	58	-3	18	0
31 Jan 17	59	-17	18	16
31 Oct 16	54	-48	19	47
31 Jul 16	41	-57	19	54
30 Apr 16	44	-1	18	0
31 Jan 16	35	-60	19	55
31 Oct 15	34	-56	19	51
31 Jul 15	31	-55	19	47
30 Apr 15	27	-54	19	43
31 Jan 15	24	-51	18	40
31 Oct 14	22	-47	18	36
31 Jul 14	23	-42	18	33
30 Apr 14	22	-36	17	28
31 Jan 14	20	-34	17	25

Kwaliteitswinsten: CDMO is momenteel verliesgevend.

Groeiende winstmarge: CDMO is momenteel verliesgevend.

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: CDMO is verliesgevend en de verliezen zijn de afgelopen 5 jaar toegenomen met een snelheid van 16.5% per jaar.

Versnelling van de groei: Het is niet mogelijk om de winstgroei van CDMO over het afgelopen jaar te vergelijken met het gemiddelde over de afgelopen vijf jaar, omdat het bedrijf momenteel verliesgevend is.

Winst versus industrie: CDMO is verlieslatend, waardoor het lastig is om de winstgroei van het afgelopen jaar te vergelijken met die van de Biotechs industrie ( 16.6% ).

Rendement op eigen vermogen

Hoge ROE: CDMO heeft een negatief Return on Equity ( -245.86% ), omdat het momenteel verliesgevend is.

Avid Bioservices Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

First quarter 2025 earnings: EPS and revenues miss analyst expectations

Avid Bioservices, Inc. to Report Q1, 2025 Results on Sep 09, 2024

Full year 2024 earnings: EPS misses analyst expectations

Avid Bioservices, Inc. to Report Fiscal Year 2024 Final Results on Jul 02, 2024

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Avid Bioservices, Inc. to Report Q2, 2024 Results on Dec 07, 2023

Recent updates

Punch and Associates Sends Letter to Board of Directors of Avid Bioservices, Inc

Funds managed by GHO Capital Partners LLP and Ampersand Management LLC entered into a definitive merger agreement to acquire Avid Bioservices, Inc. (NasdaqCM:CDMO) for approximately $850 million.

Funds managed by GHO Capital Partners LLP and Ampersand Management LLC entered into a definitive merger agreement to acquire Avid Bioservices, Inc. (NasdaqCM:CDMO) for approximately $850 million.

President exercised options and sold US$173k worth of stock

Consensus EPS estimates fall by 29%

Avid Bioservices, Inc. Reiterates Earnings Guidance for the Fiscal Year 2025

Price target increased by 14% to US$14.00

First quarter 2025 earnings: EPS and revenues miss analyst expectations

Avid Bioservices, Inc. to Report Q1, 2025 Results on Sep 09, 2024

Avid Bioservices, Inc., Annual General Meeting, Oct 16, 2024

Is Avid Bioservices (NASDAQ:CDMO) Using Too Much Debt?

Avid Bioservices, Inc. (NASDAQ:CDMO) Surges 43% Yet Its Low P/S Is No Reason For Excitement

Consensus EPS estimates fall by 21%

Full year 2024 earnings: EPS misses analyst expectations

Avid Bioservices Provides Earnings Guidance for Fiscal Year 2025

Avid Bioservices, Inc. to Report Fiscal Year 2024 Final Results on Jul 02, 2024

Insufficient new directors

Avid Bioservices Announces Receipt of Deficiency Notice from Nasdaq Regarding Late Form 10-Q

Avid Bioservices, Inc. announced delayed 10-Q filing

Avid Bioservices, Inc. announced that it expects to receive $160 million in funding

Avid Bioservices, Inc. Maintains Revenue Guidance for Full Fiscal Year 2024

There's No Escaping Avid Bioservices, Inc.'s (NASDAQ:CDMO) Muted Revenues Despite A 40% Share Price Rise

Avid Bioservices, Inc. announced that it expects to receive $160 million in funding

We Think Avid Bioservices (NASDAQ:CDMO) Has A Fair Chunk Of Debt

Insufficient new directors

There's No Escaping Avid Bioservices, Inc.'s (NASDAQ:CDMO) Muted Revenues Despite A 39% Share Price Rise

Director recently bought US$135k worth of stock

Consensus EPS estimates fall by 121%

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Avid Bioservices, Inc. Revises Revenue Guidance for the Full Fiscal Year 2024

Avid Bioservices, Inc. to Report Q2, 2024 Results on Dec 07, 2023

Does Avid Bioservices (NASDAQ:CDMO) Have A Healthy Balance Sheet?

Now 21% undervalued after recent price drop

Calculating The Intrinsic Value Of Avid Bioservices, Inc. (NASDAQ:CDMO)

Independent Chairman recently bought US$191k worth of stock

Consensus EPS estimates fall by 139%

Price target decreased by 7.2% to US$19.25

Avid Bioservices, Inc. Reiterates Revenue Guidance for Full Fiscal Year 2024

Avid Bioservices, Inc. to Report Q1, 2024 Results on Sep 07, 2023

Avid Bioservices, Inc., Annual General Meeting, Oct 23, 2023

President exercised options and sold US$254k worth of stock

Price target decreased by 11% to US$19.75

President exercised options and sold US$519k worth of stock

Consensus revenue estimates fall by 14%

Time To Worry? Analysts Are Downgrading Their Avid Bioservices, Inc. (NASDAQ:CDMO) Outlook

New minor risk - Profit margin trend

Full year 2023 earnings: EPS misses analyst expectations

Avid Bioservices, Inc. to Report Q4, 2023 Results on Jun 21, 2023

Is Avid Bioservices (NASDAQ:CDMO) Using Too Much Debt?

Little Excitement Around Avid Bioservices, Inc.'s (NASDAQ:CDMO) Earnings As Shares Take 26% Pounding

Investor sentiment deteriorates as stock falls 15%

Are Investors Undervaluing Avid Bioservices, Inc. (NASDAQ:CDMO) By 49%?

Insider notifies of intention to sell stock

Independent Director recently sold US$142k worth of stock

Director exercised options and sold US$69k worth of stock

Chief Financial Officer notifies of intention to sell stock

Third quarter 2023 earnings released

Does Avid Bioservices (NASDAQ:CDMO) Have A Healthy Balance Sheet?

Investor sentiment deteriorates as stock falls 18%

Consensus EPS estimates fall by 217%

Director exercised options and sold US$60k worth of stock

Director exercised options and sold US$57k worth of stock

Independent Director recently sold US$87k worth of stock

President exercised options and sold US$117k worth of stock

Consensus forecasts updated

Director exercised options and sold US$116k worth of stock

Avid Bioservices, Inc. Revises Revenue Guidance for the Full Fiscal Year 2023

Avid Bioservices, Inc. to Report Q2, 2023 Results on Dec 06, 2022

Here's Why Avid Bioservices (NASDAQ:CDMO) Has A Meaningful Debt Burden